- Home
- AGEN vs TRX Comparison
AGEN vs TRX Comparison
Compare AGEN & TRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- TRX
- Stock Information
- Founded
- AGEN 1994
- TRX 1990
- Country
- AGEN United States
- TRX Canada
- Employees
- AGEN N/A
- TRX N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- TRX
- Sector
- AGEN Health Care
- TRX
- Exchange
- AGEN Nasdaq
- TRX Nasdaq
- Market Cap
- AGEN 38.1M
- TRX 92.1M
- IPO Year
- AGEN 2000
- TRX N/A
- Fundamental
- Price
- AGEN $1.60
- TRX $0.30
- Analyst Decision
- AGEN Buy
- TRX Strong Buy
- Analyst Count
- AGEN 4
- TRX 2
- Target Price
- AGEN $8.00
- TRX $1.63
- AVG Volume (30 Days)
- AGEN 500.1K
- TRX 410.7K
- Earning Date
- AGEN 05-06-2025
- TRX 04-11-2025
- Dividend Yield
- AGEN N/A
- TRX N/A
- EPS Growth
- AGEN N/A
- TRX N/A
- EPS
- AGEN N/A
- TRX 0.01
- Revenue
- AGEN $103,463,000.00
- TRX $44,282,000.00
- Revenue This Year
- AGEN $4.03
- TRX $68.64
- Revenue Next Year
- AGEN $5.57
- TRX $22.37
- P/E Ratio
- AGEN N/A
- TRX $59.75
- Revenue Growth
- AGEN N/A
- TRX 16.51
- 52 Week Low
- AGEN $1.44
- TRX $0.28
- 52 Week High
- AGEN $19.69
- TRX $0.49
- Technical
- Relative Strength Index (RSI)
- AGEN 28.09
- TRX 41.84
- Support Level
- AGEN $1.44
- TRX $0.31
- Resistance Level
- AGEN $1.77
- TRX $0.33
- Average True Range (ATR)
- AGEN 0.14
- TRX 0.01
- MACD
- AGEN 0.03
- TRX -0.00
- Stochastic Oscillator
- AGEN 32.00
- TRX 5.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. Its projects include the Buckreef project, and Itetemia Gold project whereas, its exploration stage project consists of the Lunguya project and the Luhala project.